Description
An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis
Formal name: 1-[4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperidinyl]-2-hydroxy-ethanone
Synonyms: SD-006
Molecular weight: 397.9
CAS: 271576-80-8
Purity: ≥98%
Formulation: A solid